Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous …

Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …

Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy
reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI …

Purpose This phase III study investigated whether continuation maintenance with
gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with …

Background Maintenance treatment of patients with advanced non-small-cell lung cancer
(NSCLC) without disease progression after first-line chemotherapy is a subject of ongoing …

Purpose To establish a baseline for care and overall survival (OS) based upon
contemporary first-line treatments prescribed in the era before the introduction of immune …

Background: The current oncologic management of non–small cell lung cancer (NSCLC)
requires pathologic differentiation between adenocarcinoma and squamous cell carcinoma …

Lung cancer is the most common cause of cancer deaths. Most patients present with
advanced-stage disease, and the prognosis is generally poor. However, with the …

Background Pruritus has been anecdotally described in association with targeted cancer
therapies. The risk of pruritus has not been systematically ascertained. Objective A …

The advent of targeted anticancer therapies over the past few decades has reinvigorated the
field of cancer therapeutics, with the promise of increased cancer cure rates accompanied …